NO20130366A1 - Bruk av bindemidler for fremstilling av lagringsstabile formuleringer - Google Patents

Bruk av bindemidler for fremstilling av lagringsstabile formuleringer Download PDF

Info

Publication number
NO20130366A1
NO20130366A1 NO20130366A NO20130366A NO20130366A1 NO 20130366 A1 NO20130366 A1 NO 20130366A1 NO 20130366 A NO20130366 A NO 20130366A NO 20130366 A NO20130366 A NO 20130366A NO 20130366 A1 NO20130366 A1 NO 20130366A1
Authority
NO
Norway
Prior art keywords
oxycodone
pharmaceutically acceptable
acceptable salt
naloxone
hci
Prior art date
Application number
NO20130366A
Other languages
English (en)
Norwegian (no)
Inventor
Derek Allan Prater
Udo Hahn
Christof Spitzley
Gerhard Josef Heun
Alexander Schuetz
Christian Leuner
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20130366(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20130366A1 publication Critical patent/NO20130366A1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20130366A 2010-08-13 2013-03-12 Bruk av bindemidler for fremstilling av lagringsstabile formuleringer NO20130366A1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37334410P 2010-08-13 2010-08-13
EP10172759 2010-08-13
PCT/EP2011/063864 WO2012020097A2 (en) 2010-08-13 2011-08-11 Use of binders for manufacturing storage stable formulations

Publications (1)

Publication Number Publication Date
NO20130366A1 true NO20130366A1 (no) 2013-04-29

Family

ID=43382375

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20130366A NO20130366A1 (no) 2010-08-13 2013-03-12 Bruk av bindemidler for fremstilling av lagringsstabile formuleringer

Country Status (29)

Country Link
US (2) US20130245054A1 (de)
EP (2) EP3505162A1 (de)
JP (1) JP6007176B2 (de)
KR (1) KR101518143B1 (de)
CN (1) CN103118668B (de)
AR (1) AR082688A1 (de)
AU (1) AU2011288413B2 (de)
BR (1) BR112013003150B1 (de)
CA (1) CA2805974C (de)
CH (1) CH705678B1 (de)
CL (1) CL2013000444A1 (de)
CO (1) CO6680640A2 (de)
DE (1) DE112011102708T5 (de)
DK (1) DK178702B1 (de)
EC (1) ECSP13012467A (de)
ES (1) ES2409069B2 (de)
GB (1) GB2495676B (de)
MX (1) MX355644B (de)
MY (1) MY165149A (de)
NO (1) NO20130366A1 (de)
NZ (1) NZ606123A (de)
PE (1) PE20131101A1 (de)
PH (1) PH12013500172A1 (de)
RU (1) RU2572695C2 (de)
SE (1) SE537698C2 (de)
SG (1) SG187678A1 (de)
SI (1) SI2603205T1 (de)
TW (1) TWI469781B (de)
WO (1) WO2012020097A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1492505B1 (de) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmazeutische zubereitung enthaltend oxycodon und naloxon
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2568965A1 (de) 2010-05-10 2013-03-20 Euro-Celtique S.A. Kombination aus aktivem beladenem granulat mit zusätzlichen aktivstoffen
PH12012502083A1 (en) 2010-05-10 2017-07-26 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
KR102640668B1 (ko) * 2017-04-13 2024-02-23 장 폴 레몬 잔토휴몰-계 조성물
CN111686094A (zh) * 2020-07-13 2020-09-22 云南民族大学 一种脂肪醇类化合物在制备通便药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3581428D1 (de) 1984-06-13 1991-02-28 Roehm Gmbh Verfahren zum ueberziehen von arzneiformen.
EP1442745A1 (de) * 1993-10-07 2004-08-04 Euro-Celtique Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
JP4848558B2 (ja) * 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
JP2003160487A (ja) * 2001-11-20 2003-06-03 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウム含有錠剤およびその製造法
EP1492505B1 (de) * 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmazeutische zubereitung enthaltend oxycodon und naloxon
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
DE102005048293A1 (de) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retardformulierung für Pralnacasan
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
JP2009298707A (ja) * 2008-06-11 2009-12-24 Ohara Yakuhin Kogyo Kk 粒子加工方法
WO2010099508A1 (en) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Also Published As

Publication number Publication date
DE112011102708T5 (de) 2013-05-29
WO2012020097A3 (en) 2012-05-03
RU2013110820A (ru) 2014-09-20
GB2495676A (en) 2013-04-17
PE20131101A1 (es) 2013-09-23
JP6007176B2 (ja) 2016-10-12
EP3505162A1 (de) 2019-07-03
GB2495676B (en) 2018-08-22
MX2013001757A (es) 2013-05-06
SI2603205T1 (sl) 2019-02-28
AR082688A1 (es) 2012-12-26
TW201228662A (en) 2012-07-16
EP2603205A2 (de) 2013-06-19
RU2572695C2 (ru) 2016-01-20
KR20130083903A (ko) 2013-07-23
GB201301916D0 (en) 2013-03-20
NZ606123A (en) 2015-03-27
BR112013003150A2 (pt) 2020-09-08
ES2409069R1 (es) 2013-08-30
CL2013000444A1 (es) 2013-08-23
WO2012020097A2 (en) 2012-02-16
JP2013533303A (ja) 2013-08-22
PH12013500172A1 (en) 2022-10-24
CA2805974C (en) 2019-11-26
US20130245054A1 (en) 2013-09-19
EP2603205B1 (de) 2018-10-03
AU2011288413A1 (en) 2013-02-21
CN103118668B (zh) 2016-07-06
ES2409069B2 (es) 2014-07-17
ECSP13012467A (es) 2013-03-28
CN103118668A (zh) 2013-05-22
SG187678A1 (en) 2013-03-28
TWI469781B (zh) 2015-01-21
ES2409069A2 (es) 2013-06-24
CO6680640A2 (es) 2013-05-31
DK178702B1 (en) 2016-11-21
CA2805974A1 (en) 2012-02-16
SE537698C2 (sv) 2015-09-29
AU2011288413B2 (en) 2014-05-22
CH705678B1 (de) 2016-03-15
MY165149A (en) 2018-02-28
MX355644B (es) 2018-04-26
KR101518143B1 (ko) 2015-05-06
SE1350286A1 (sv) 2013-03-21
DK201370075A (en) 2013-02-13
BR112013003150B1 (pt) 2022-01-18
US20160095853A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
NO20130366A1 (no) Bruk av bindemidler for fremstilling av lagringsstabile formuleringer
AU2013344281B2 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
US9717701B2 (en) Compositions for overcoming resistance to tramadol
CA2739751C (en) Pharmaceutical compositions comprising hydromorphone and naloxone
KR20180016651A (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
WO2022125007A1 (en) Prolonged release mirabegron formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application